What is claimed is:

1. A process for preparing an extract of *Crassocephalum crepidioides* comprising the steps of:

(a) contacting *Crassocephalum crepidioides* plant with 70% ethanol to obtain a suspension;

(b) separating the suspension into a solid portion and a liquid portion, and then collecting the liquid portion to obtain a crude extract;

(c) diluting the crude extract to a 60% ethanol extract;

(d) mixing the 60% ethanol extract with macroporous styrene-divinyl benzene resins;

(e) pouring the 60% ethanol extract and macroporous styrene-divinyl benzene resin mixture into a column;

(f) washing the column with ethanol at a volume of about 2- to 10-fold to the volume of the column;

(g) eluting the column with a solvent of ethanol/ethyl acetate or ethyl acetate and collecting the eluted fractions at different time intervals; and

(h) analyzing each eluted fraction and determining which one is enriched in 1,2-di-O-α-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG) and contains phytol as the *Crassocephalum crepidioides* extract.

2. The process according to claim 1, wherein the *Crassocephalum crepidioides* plant is the whole plant.

3. The process according to claim 1, wherein the *Crassocephalum crepidioides* plant is selected from seeds, flowers, leaves, or any combination thereof.

4. The process according to any one of claims 1 to 3, wherein the *Crassocephalum crepidioides* plant is dried and powdered.

5. The process according to claim 4, wherein the *Crassocephalum crepidioides* plant is a dried plant and the ratio of the weight of the dried plant to the volume of the 70% ethanol solvent in step (a) ranges from about 1:1 to about 1:50.

6. The process according to any one of claims 1 to 5, wherein the ratio of the weight of the dried plant to the volume of the 70% ethanol solvent in step (a) is about 1:10.

7. The process according to any one of the preceding claims, wherein the macroporous styrene-divinyl benzene resin is selected from Sepabeads SP70 and Sepabeads SP710.

8. The process according to claim 7, wherein the macroporous styrene-divinyl benzene resin is Sepabeads SP70.

9. The process according to claim 1, wherein the solvent used in step (g) is ethanol/ethyl acetate, and wherein the volume ratio of ethanol to ethyl acetate is about 1:1.

10. A *Crassocephalum crepidioides* extract obtainable from the process according to any one of claims 1 to 9.

11. The *Crassocephalum crepidioides* extract according claim 10, which has 7 main peaks at the retention times of 12.59 min, 12.893 min, 13.828 min, 14.158 min, 14.922 min, 15.455 min, and 16.478 min, respectively, when determined by HPLC at the following conditions:

Column: Symmetry Shield C18, 15 μm, 4.6 x 150 mm

Temperature: ambient

Elution: H_2O/CH_3CN gradient

Detection: UV 210 nm

Time (min)	Mobile phase (%)	
	H_2O	CH_3CN
0	35	65
10	3.5	96.5
20	3	97
22	0	100
27	0	100
28	35	65
35	35	65

12. A pharmaceutical composition comprising a therapeutically effective amount of the *Crassocephalum crepidioides* extract according to claim 10 or 11 and a pharmaceutically acceptable carrier.

13. A pharmaceutical combination comprising a therapeutically effective amount of the *Crassocephalum crepidioides* extract according to claim 10 or 11 and a chemotherapeutic agent.

14. The pharmaceutical combination according to claim 13, wherein the chemotherapeutic agent is selected from a antimetabolite, an alkylating agent, an

anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

15. The pharmaceutical combination according to claim 13 or 14, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.

16. Use of the *Crassocephalum crepidioides* extract according to claim 10 or 11 or the pharmaceutical combination according to any one of claims 12 to 15 in the manufacture of a medicament for treating or preventing cancer in a subject in need.

17. Use of the *Crassocephalum crepidioides* extract according to claim 10 or 11 or the pharmaceutical combination according to any one of claims 12 to 15 in the manufacture of a medicament for treating or preventing cancer in a subject in need in combination with a chemotherapeutic agent.

18. The use according to claim 17, wherein the chemotherapeutic agent is selected from an antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

19. The use according to claim 17 or 18, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.

20. The *Crassocephalum crepidioides* extract according to claim 10 or 11 or the pharmaceutical combination according to any one of claims 12 to 15 for use in treating or preventing cancer.

21. The *Crassocephalum crepidioides* extract according to claim 10 or 11 or the pharmaceutical combination according to any one of claims 12 to 15 for use in treating or preventing cancer in combination with a chemotherapeutic agent.

22. The *Crassocephalum crepidioides* extract or the pharmaceutical combination according to claim 21, wherein the chemotherapeutic agent is selected from an antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

23. The *Crassocephalum crepidioides* extract or the pharmaceutical combination according to claim 21or 22, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.